Biomarkers for Memory Loss
Can predict among cognitive normal who will progress to disease Minimally-invasive (as opposed to lumbar puncture)Low cost (low tech, as opposed to neuroimaging)Quick, familiar, and easily tolerated by most individualsThese biomarkers define the asymptomatic period in patients and are critical for successful development and application of the therapeutics. The preclinical state of the disease offers a window of opportunity for timely disease-modifying intervention.
Dr. Federoff and his team have discovered several biomarkers including but not limited to lipids, metabolites, genes and proteins in the blood that can predict with close to 100% accuracy if a healthy person will develop mild cognitive impairment or Alzheimer’s disease (AD). Existing preclinical biomarkers of AD are obtained either through time-consuming and expensive neuroimaging modalities, or via invasive and risky lumbar punctures for cerebrospinal fluid analyses. The present invention has a potential for a powerful blood test to identify people at risk for progressive cognitive decline. Further, the novel method has a potential to be used in selecting individuals for secondary prevention trials and to provide clues for targeted therapeutic interventions.
美国
